Theresa Heggie sold $596K of BioCryst Pharmaceuticals (BCRX)

Executed Aug 13 2025, disclosed Aug 15 2025, 2 days later.

Value, as filed

$596K

70,000 sh × $8.51

Executed

Aug 13 2025

the trade date, as filed

Disclosed

Aug 15 2025

2 days after the trade

Return, 21 sessionsiFrom the disclosed entry session; derived

–

purchases only

Returns are measured on stock purchases only.

The filer

TH Theresa Heggie Director profile →

Theresa Heggie (Director) filed 1 Form 4 report in the trailing twelve months (0 purchases, 1 sale), most often in BioCryst Pharmaceuticals, Inc. (BCRX). The largest single filing was $505K of BCRX (49,933 sh × $10.11, as filed), executed Mar 20.

The name

BCRX BioCryst Pharmaceuticals, Inc. BCRX · Healthcare · 10 filings in 24 months ticker →

Healthcare · BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other…

More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→

Other filings by Theresa Heggie in BCRX

BCRXSALE BioCryst Pharmaceuticals, Inc. $505K
49,933 sh × $10.11
Exec Mar 20
Filed Mar 24 · 5:30 PM ET